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Morphine, the opioid analgesic most abundantly used for
severe acute and chronic pain, is associated with several
adverse effects such as respiratory depression, tolerance
and dependence. The intensive search to find new opioids
possessing a better pharmacological profile has resulted in
14-O-methyloxymorphone (14-O-MOX) and 14-meth-
oxy-metopon (MET), a highly μ-selective and very potent
opioid agonist. Our aim was to test the compounds in the
rat vas deferens (RVD) bioassay system in order to further
analyze their μ receptor efficacy and elucidate the struc-
ture-activity relationship between the compounds and
oxymorphone (OX), their parent molecule. RVD was pre-
pared, mounted and stimulated as described by Ronai et
al. [1]. Opioid actions were measured by determining the
inhibitory effects on the electrically evoked twitches.
Antagonist activity was determined by the single-dose
method. MET exerted full agonist activity in RVD, unlike
OX and 14-O-MOX which were only partial agonists. Nal-
trexone, the reference μ receptor antagonist, antagonized
the inhibitory actions on the electrically evoked twitches
of the test compounds with a similar potency than in
mouse vas deferens indicating the presence of μ opioid
receptors in RVD. We found that MET is a highly effica-
cious μ receptor agonist and that the 5-methyl substitu-
tion may be responsible for the full agonist activity. We
could not prove the distinction between rat vas deferens
and other μ receptor-containing organs.
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